Colorado's State Flower
A columbine in Golden Gate Canyon State Park near Boulder
So far I have written 375 articles for the Health Central Network about all aspects of diabetes. In April this great website published nine more of my new diabetes articles:
David Kliff calls bariatric surgery "the ultimate failure." I heartily agree. The publisher of "Diabetic Investor" newsletter authorized me to reproduce his article here.
If you have any interest in controlling your diabetes by low-carb eating, one of the best resources is Dr. Richard K. Bernstein's monthly webcast. It's an hour of excellent diabetes education.
Dr. Bernstein's next live Tele-Seminar is Wednesday, May 27, at 8:00 PM EST, 7:00 PM CST, 6:00 PM MST, and 5:00 PM PST. He designed it to answer your most important questions concerning diabetes and to offer his thoughts on the latest developments in this area. The seminar is free. You can click here to register: http://www.diabetes911.net/askdrb/index.php. It's also available as a live webcast both on the Internet and by phone.
At the beginning of the call Dr. Bernstein will provide new information that is not in his books.
DEFEND-1 stands for Durable-response therapy Evaluation For Early or New-onset type 1 Diabetes. DEFEND-1 is a Phase 3 clinical study evaluating a new investigational agent called otelixizumab (oh' te lix iz' oo mab).
They are currently recruiting for DEFEND-1. In type 1 diabetes, beta cells (the cells that make insulin) are destroyed by the body's immune system. If this destruction could be slowed or stopped, a person could continue to make some of his or her own insulin. This would result in better control of blood sugar levels while using less exogenous insulin.
Otelixizumab is now being tested in a Phase 3 clinical study to see if it can reduce the destruction of beta cells in people with type 1 diabetes. It is an investigational agent, which means it has not been approved by the Food and Drug Administration (FDA) for marketing. It is not yet known whether otelixizumab will be effective against type 1 diabetes.
Please visit the website: www.T1trial.com; and feel free to contact them with any questions at 1-866-954-0024 or email them at [email protected].
Announcements
The Health Central Network will now notify you by email of new articles (SharePosts) by me or anyone who posts at HealthCentral.com. Just click on "Subscribe" at the top of each of my articles or on my "Profile" page.
Each month I describe and link my new Health Central articles here. But you can also use a blog reader to keep up with my articles more quickly. I use Bloglines, as I describe in my article, “Reading Health Blogs.” Go to bloglines.com, click on feeds, click on add, (both in left pane), then in center pane enter at “Blog or Feed URL” click on www.healthcentral.com/diabetes/c/17/rss/. Alternatively, you can subscribe to my new articles at Health Central by taking your browser to http://www.bloglines.com/sub/http://www.healthcentral.com/diabetes/c/17/.
Diabetes Update keeps you up-to-date with new articles, Web pages, and books that I have written about diabetes.
I list and link most of these on my at Diabetes Directory and in the site’s menu at the upper left of all my Web pages.
From time to time Diabetes Update may also include links to other Web pages of special interest.
I send out Diabetes Update email in HTML format, which all Web browsers and most modern email programs can display. HTML has live links to all the sites named in the text so that with a simple click of a mouse you can connect to the site you have just been reading about.
This newsletter:
- Is and will remain free.
- Will never include advertising (except targeted Google ads at the bottom of the web page and not in the email newsletter).
- Nor will I ever sell, rent, or trade your email address to anyone.
- I will link sources of information.
- I will disclose any conflict of interest.
- If and when I learn of any errors of fact, I will correct them.
Archives: I now send out Diabetes Update once a month.
